scholarly journals Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

2008 ◽  
Vol 10 (5) ◽  
pp. R124 ◽  
Author(s):  
Carlotta Nannini ◽  
Colin P West ◽  
Patricia J Erwin ◽  
Eric L Matteson
Keyword(s):  
Systematic Review ◽  
Interstitial Lung Disease ◽  
Pulmonary Function ◽  
Cohort Studies ◽  
Randomized Controlled Trials ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Prospective Cohort Studies ◽  
Randomized Controlled

scholarly journals Nonnutritive sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies

2017 ◽  
Vol 189 (28) ◽  
pp. E929-E939 ◽  
Author(s):  
Meghan B. Azad ◽  
Ahmed M. Abou-Setta ◽  
Bhupendrasinh F. Chauhan ◽  
Rasheda Rabbani ◽  
Justin Lys ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Randomized Controlled Trials ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Cardiometabolic Health ◽  
Controlled Trials ◽  
Prospective Cohort Studies ◽  
Randomized Controlled

scholarly journals Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 Randomized Controlled Trials and 15 Prospective Cohort Studies

2021 ◽  
Vol 8 ◽  
Author(s):  
Lin Xu ◽  
Zezhong Tian ◽  
Hong Chen ◽  
Yimin Zhao ◽  
Yan Yang
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cardiovascular Risks ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Prospective Cohort Studies ◽  
Randomized Controlled

Objective: The associations between intake of anthocyanins and anthocyanin-rich berries and cardiovascular risks remained to be established. We aimed to quantitatively summarize the effects of purified anthocyanins and anthocyanin-rich berries on major surrogate markers of cardiovascular diseases (CVDs) and the longitudinal associations between dietary anthocyanins and CVD events.Methods: Meta-analysis of randomized controlled trials (RCTs) and prospective cohort studies.Results: We included 44 eligible RCTs and 15 prospective cohort studies in this study. Pooled analysis of RCTs showed that purified anthocyanin supplementation could significantly reduce blood LDL cholesterol (weighted mean difference (WMD): −5.43 mg/dL, 95% CI: −8.96, −1.90 mg/dL; p = 0.003) and triglyceride (WMD: −6.18 mg/dL, 95% CI: −11.67, −0.69 mg/dL; p = 0.027) while increase HDL cholesterol (WMD: 11.49 mg/dL, 95% CI: 7.43, 15.55 mg/dL; p < 0.001) concentrations. Purified anthocyanins also markedly decreased circulating tumor necrosis factor alpha (WMD: −1.62 pg/mL, 95% CI: −2.76, −0.48 pg/mL; p = 0.005) and C-reactive protein (WMD: −0.028 mg/dL, 95% CI: −0.050, −0.005 mg/dL; p = 0.014). Besides, administration of anthocyanin-rich berries could significantly lower blood total cholesterol (WMD: −4.48 mg/dL, 95% CI: −8.94, −0.02 mg/dL; p = 0.049) and C-reactive protein (WMD: −0.046 mg/dL, 95% CI: −0.070, −0.022 mg/dL; p < 0.001). Neither purified anthocyanins nor anthocyanin-rich berries could cause any substantial improvements in BMI, blood pressure, or flow-mediated dilation. In addition, meta-analysis of prospective cohort studies suggested that high dietary anthocyanins were related to lower risk of coronary heart disease (CHD) (relative risk (RR): 0.83, 95% CI: 0.72, 0.95; p = 0.009), total CVD incidence (RR: 0.73, 95% CI: 0.55, 0.97; p = 0.030), and total CVD deaths (RR: 0.91, 95% CI: 0.87, 0.96; p < 0.001).Conclusion: Habitual intake of anthocyanins and anthocyanin-rich berries could protect against CVDs possibly via improving blood lipid profiles and decreasing circulating proinflammatory cytokines.Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO, identifier: CRD42020208782.

scholarly journals Association of incident dialysis modality with mortality: a protocol for systematic review and meta-analysis of randomized controlled trials and cohort studies

2019 ◽  
Vol 8 (1) ◽  
Author(s):  
Mark R. Marshall ◽  
Chun-Yuan Hsiao ◽  
Philip K. Li ◽  
Masaaki Nakayama ◽  
S. Rabindranath ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Dialysis Modality ◽  
Randomized Controlled

scholarly journals Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials

2007 ◽  
Vol 86 (6) ◽  
pp. 1780-1790 ◽  
Author(s):  
Heike A Bischoff-Ferrari ◽  
Bess Dawson-Hughes ◽  
John A Baron ◽  
Peter Burckhardt ◽  
Ruifeng Li ◽  
...  
Keyword(s):  
Hip Fracture ◽  
Cohort Studies ◽  
Fracture Risk ◽  
Calcium Intake ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Men And Women ◽  
Prospective Cohort Studies ◽  
Randomized Controlled

Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 1072-1072
Author(s):  
Nusrat Jahan ◽  
Sariya Wongsaengsak ◽  
Shabnam Rehman ◽  
Myrian Vinan-Vega ◽  
Lukman Aderoju Tijani ◽  
...  
Keyword(s):  
Systematic Review ◽  
Relative Risk ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cyclin Dependent Kinase ◽  
Phase 3 ◽  
Randomized Controlled

1072 Background: All three currently approved cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) such as palbociclib, abemaciclib, and ribociclib are reported to cause significant pulmonary toxicities including fatal pneumonitis or interstitial lung disease (ILD). We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials (RCTs) to determine the relative risk of pneumonitis or ILD associated with CDK4/6i. Methods: We conducted a systematic search using PRISMA guidelines in PubMed, EMBASE, American Society of Clinical Oncology and San Antonio Breast Cancer Symposium meeting abstracts from inception through Jan 30, 2021. Phase 3 RCTs using CDK4/6i in the intervention arm and reporting the number of events for pneumonitis or ILD were included in the analysis. The Cochran-Mantel-Haenszel method and random effects model were used to calculate the pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was tested by Cochran’s Q test and I2 value. Results: Five phase 3 RCTs — MONALEESA-3, MONALEESA-7, MONARCH plus, monarchE, and PALLAS — reported the number of events for any grade pneumonitis or ILD and were included in the final analysis. A total of 13,191 patients — 6,758 in the CDK4/6i arm and 6,433 in the control arm — were analyzed. Following regimens were used in CDK4/6i arms — MONALEESA-3: ribociclib + fulvestrant; MONALEESA-7: ribociclib + tamoxifen or a non-steroidal aromatase inhibitor + goserelin; MONARCH plus: in cohort A, abemaciclib + anastrozole or letrozole, and in cohort B, abemaciclib + fulvestrant; MonarchE: abemaciclib + standard-of-care adjuvant endocrine therapy (ET); PALLAS: Palbociclib + ET. In the control arms, all studies used placebo and respective endocrine therapies. Any grade pneumonitis or ILD was reported in 1.64% of patients in the CDK4/6i arm versus 0.68% of patients in the control arm. The pooled RR of any grade pneumonitis or ILD was 2.26, 95% CI: 1.60-3.19, P < 0.00001, I2 = 0%. Grade 3/4 pneumonitis or ILD was reported in 0.28% of patients in the CDK4/6i arm and 0.06% of patients in the control arm with pooled RR of 2.35, 95% CI: 0.37-15.08, P = 0.37, I2 = 34%. One grade 5 pneumonitis was reported in the monarchE. Conclusions: Cyclin-dependent kinase 4/6 inhibitors are associated with increased risk of any grade pneumonitis or ILD. Early detection and prompt initiation of appropriate interventions are vital to reduce the morbidity and mortality associated with CDK4/6i induced pneumonitis or ILD.

Sign in / Sign up

Export Citation Format

Share Document